- Global Pharma News & Resources

Glioblastoma Multiforme Treatment Market is estimated to expand at a CAGR of 7.5% from 2023 to 2032 | insightSLICE

The global Glioblastoma Multiforme Treatment market is predicted to be worth US$ 2.3 billion in 2021, with a 7.5% CAGR from 2023 to 2032.

Glioblastoma multiforme (GBM) is a malignant tumor classified as grade IV by the World Health Organization. GBM is the most prevalent medically diagnosed oncological disorder of the central nervous system (CNS). These malignancies are described even in ancient medical reports in a broad wide range of ways.

The use of genetic and molecular tests has proven the multiformity of GBM. Different genotypes have comparable histomorphology and IHC images, as well as some characteristics of gliomagenesis.

Access the sample report:

Global Glioblastoma Multiforme Treatment Market Key Segments:

By Type

  • Primary (De Novo)
  • Secondary

By Treatment

  • Surgery
  • Radiotherapy
  • Medications

By Patient Type

  • Adult
  • Geriatric
  • Child

By Drug Type

  • Branded
  • Generics

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End User

  • Hospitals
  • Clinics
  • Home Healthcare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By  Geography

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

A particular trigger mutation in a GBM stem cell is required for primary glioblastoma multiforme to emerge, whereas a slow accumulation of multiple mutations without the need for a distinct trigger mutation is required for secondary GBM to occur. GBM understanding has been strongly linked to the medical expertise of the CNS since such tumors were first identified more than 200 years ago.

Because of the increased demand for glioblastoma multiforme treatment, companies are boosting their supply of new products and technology pipelines. Moreover, there is greater activity participation in the market, which eventually boosts the market growth.

The key players of the Global Glioblastoma Multiforme Treatment Market are:

Some of the major players present in the Glioblastoma Multiforme Treatment Market report are Amgen Inc, Accord Healthcare, Angiochem, ANI Pharmaceuticals Inc, Arbor Pharmaceuticals LLC, AstraZeneca, Amneal Pharmaceuticals LLC, Cantex Pharmaceuticals Inc, Celon LABS, Diffusion Pharmaceuticals Inc, EnGeneIC, ERC.SA., Eckert & Ziegle, Genenta science, Hoffmann-La Roche AG, Jazz Pharmaceuticals Inc, Loxo Oncology, Merck & Co Inc, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, VBL Therapeutics, Viatris Inc, Varian Medical Systems Inc, ZEISS International, Zydus Pharmaceuticals Incand others.

Read more about the report inclusions:

Driving factors for the growth of Global Glioblastoma Multiforme Treatment Market

Patients and clinicians all over the world seek early detection and diagnosis of Glioblastoma multiforme. The introduction of new technology has accelerated the worldwide glioblastoma multiforme treatment market.

Tumor heterogeneity and variance in treatment approach from patient to patient are also predicted to contribute to a rise in demand for a customized therapy approach to control glioblastoma multiforme.

The adoption of new medicines or repurposing of existing ones is projected to extend the life expectancy of glioblastoma multiforme patients. These factors will enable fast growth in the global glioblastoma multiforme treatment market in the forecast period.

Every year, new biological treatments are developed as a result of increased R&D activity in molecular biotechnology and new cancer therapies. These new medications help to reduce therapy adverse effects and increase patient acceptance.

The approval of new therapy options will extend the lives of patients suffering from glioblastoma multiforme. Moreover, increased partnerships between pharmaceutical scientists and companies would support the expansion of this industry.

Because of the disease’s high fatality rate, the glioblastoma multiforme treatment market has seen multiple medication approvals in recent years. Furthermore, the increased activity of regulatory bodies to authorize innovative medicines has boosted the market growth.

Regional performance of Glioblastoma Multiforme Treatment Market

In 2020, North America held the highest share (43.6%). Government assistance for the expansion of the healthcare sector, widespread knowledge of rare disorders, quick access to high-quality medical facilities, and advantageous reimbursement policies are some of the important drivers driving the regional market growth.

Asia Pacific is predicted to expand at the quickest pace of 10.2% during the forecast period, due to reasons such as the introduction of generic temozolomide into the marketplace, an improved economy, an aging population, and more investment in the healthcare industry.

The presence of substantial unmet demands in the market, the improved experience of GBM, and the existence of a strong portfolio are among the primary drivers driving the regional market growth.

Related reports:

Global Mobile Hemodialysis Machine Market:

Global Full Acrylic Denture Market:

Challenges of Global Glioblastoma Multiforme Treatment Market

Glioblastoma multiforme is typically diagnosed at an advanced stage, resulting in a terrible prognosis. Drug development for GBM is a time-consuming and expensive procedure that necessitates major investments, clinical testing experience, process improvement, academic requirements, and technological abilities.

Due to the severe regulations imposed by regulators, drug makers are compelled to invest in clinical studies and article safety control procedures. The high cost of managing GBM with novel and improved medications will function as a major impediment to the expansion of this industry.

Because of higher survival rates, radiation therapy dominated the market with a revenue share of 37.6% in 2020. Radiation therapy can be used as the primary treatment or in conjunction with chemotherapy and surgery. It is also helpful and strongly recommended for recurrent brain tumors.

For example, the combination of temozolomide and radiotherapy renders cancer more responsive to irradiation. Such a combination of therapies is more successful than radiotherapy alone. Due to these factors, the market is projected to show growth for various types of therapies as the number of patients increases.

Another usual treatment for GBM is surgery, which is followed by radiation therapy and chemotherapy. This treatment regimen is considered the gold standard of GBM therapy.

Furthermore, the growing usage of personalized therapy to treat GBM is likely to drive the growth of this segment during the projection period. Rising research efforts to discover novel targeted therapies for the condition are also expected to drive category growth.

Proceed to purchase:

insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at

Contact us:

Alex R

+1 707 736 6633

Linkedin | Twitter

Editor Details

Last Updated: 10-Nov-2022